The purpose of this study is to better estimate the prevalence of urinary tract infections (UTI) in kidney transplant (KIT) recipients, and especially multidrug resistant (MDR) bacteria. KIT recipients have a higher risk of UTI over the 6 first months following the transplantation. Urine culture was done in a city lab or at hospital. Current data on bacteriuria and candiduria lead mostly to hospital data that are incomplete..
The risk of UTI after a kidney transplantation is higher than in the general population. MDR bacteria, such as extended spectrum betalactamase (ESBL)-producing enterobacteriaceae or MDR Pseumomoas aeruginosa are emerging threats due to antibiotic selective pressure. Epidemiological data are mostly data from hospital laboratories that do not show a complete overview of the current situation. In addition, the different centers which participated to this study received before the beginning of the study a protocol to avoid carbapenem use. The main objective of this study is to assess the prevalence of MDR bacteria in an adult population of KIT recipients. Through this study, the management of UTI in KIT recipients will be improved. Data on bacteria or yeasts responsible for UTI (identification, resistance profile), antibiotic use, patients' outcome, and graft outcome will be collected.
Study Type
OBSERVATIONAL
Enrollment
120
No intervention
CHU de Poitiers
Poitiers, France
RECRUITINGAssessment of UTI due to MDR bacteria
Proportion of MDR bacteria compared to other bacteria found in urinalysis of symptomatic KIT patients
Time frame: Day 0 to 2 years
Epidemiology of UTI in KIT recipients
Frequency of each bacteria or yeasts responsible for UTI
Time frame: Day 0 to 2 years
Risk factors for MDR UTI
Comparison of demographic and clinical characteristic of patients who develop an MDR versus a non-MDR UTI
Time frame: Day 0 to 2 years
Carbapenem use to treat UTI
Proportion of patients who received carbapenem for UTI treatment
Time frame: Day 0 to 2 years
Coherence between antibiotic protocol and treatment received to treat UTI
Proportion of patients who received carbapenem while responsible bacteria was susceptible to other antibiotics
Time frame: Day 0 to 2 years
UTI relapse frequency
Proportion of patients with at least one relaspe of UTI with the same bacteria
Time frame: Day 0 to 2 years
UTI recurrence frequency with a different micororganism
Proportion of patients with more than one UTI during the study period
Time frame: Day 0 to 2 years
Assessment of kidney function during the observation period
Difference between the initial kidney function (MDRD) and the final kidney function at the end of the observation period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Day 0 to 2 years
Graft outcome
Number of patients needed a dialysis
Time frame: Day 0 to 2 years
Patients outcome
Number of deaths
Time frame: Day 0 to 2 years